Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
Authors:
Open Access
- 14 August 2024
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 131 (7) , 1178-1185
Abstract
Background: We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care. Methods: A decision analytic model was completed from the healthcare payer’s perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA). Results: The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations. Conclusions: Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.Keywords
Funding Information
- Canadian Partnership Against Cancer Corporation www.partnershipagainstcancer.ca
- Canadian Partnership Against Cancer Corporation https://www.partnershipagainstcancer.ca/
This publication has 33 references indexed in Scilit:
- Cost-effectiveness of Implementing Smoking Cessation Interventions for Patients With CancerJAMA Network Open, 2022
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluationsHealth Policy OPEN, 2022
- Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year dataJournal of Medical Economics, 2021
- Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With CancerJAMA, 2020
- 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation TreatmentJACC, 2018
- 21st-Century Hazards of Smoking and Benefits of Cessation in the United StatesNew England Journal of Medicine, 2013
- A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 UpdateAmerican Journal of Preventive Medicine, 2008
- Smoking has a negative impact upon health related quality of life after treatment for head and neck cancerOral Oncology, 2007
- Association between smoking during radiotherapy and prognosis in head and neck cancer: A follow‐up studyHead & Neck, 2002
- Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatmentAddictive Behaviors, 1978